• About
  • Advertise
  • Newsroom
  • Contact Us
Wednesday, February 8, 2023
No Result
View All Result
NEWS ALERTS
GantNews.com
62 °f
Clearfield
  • Home
  • Top Stories
  • News
    • Top Stories
    • A & E
    • Business News
    • Crime
    • Local News
    • Explore Jefferson
    • Features
    • Health News
      • Health & Wellness
    • Sports
      • Local Sports
  • Obituaries
  • Opinions
  • Classifieds
    • Real Estate
  • Health & Wellness
  • Home
  • Top Stories
  • News
    • Top Stories
    • A & E
    • Business News
    • Crime
    • Local News
    • Explore Jefferson
    • Features
    • Health News
      • Health & Wellness
    • Sports
      • Local Sports
  • Obituaries
  • Opinions
  • Classifieds
    • Real Estate
  • Health & Wellness
No Result
View All Result
GantNews.com
No Result
View All Result
ADVERTISEMENT
Home Coronavirus Updates

Wolf Administration Highlights Development of Promising New Drug Candidate to Treat COVID-19

by Gant Team
Thursday, December 10, 2020
in Coronavirus Updates, Health & Wellness, Health News, Local News
0
0
0
SHARES
0
VIEWS
Share on FacebookShare on Twitter

HARRISBURG – On Wednesday, Department of Community and Economic Development (DCED) Deputy Secretary Steve D’Ettorre and Ben Franklin Technology Partners Innovation Works Chief Executive Officer Richard Lunak joined Teresa Whalen, CEO of Pittsburgh-based CytoAgents, to highlight the development of a new COVID-19 treatment.

“This exciting new development was made possible by the strong partnerships the Wolf Administration has fostered with our Ben Franklin Technology Partners and the companies they support, like CytoAgents,” said D’Ettorre.

“We know that the investments we make in these innovative companies today will pay dividends tomorrow, and the work that CytoAgents is doing, and the support they’re receiving from Innovation Works, will inspire hope and, quite literally, save countless lives.”

CytoAgents, a Ben Franklin Technology Partners company, has begun its Phase 1 clinical trial for COVID-19 treatment. The leading drug candidate, GP1681, combats “cytokine storm,” clinically known as hypercytokinemia, a severe immune reaction.

“Innovation Works provides capital, expertise, and resources to highly promising startups in Southwest PA,” said Lunak.  “But the real work comes from innovative companies like CytoAgents.

 “These startups are creating the technologies and innovations that will improve the nature of our society while building those successful companies here in Pennsylvania and adding to our dynamic economy.”

GP1681, a small molecule inhibitor of cytokine release, addresses an unmet need for therapeutic treatment. It has been shown to tamp down various cytokines and address the underlying cause of life-threatening symptoms associated with cytokine storm.

GP1681 will be an affordable, oral therapeutic and an important component of a multi-faceted treatment plan.

The Phase 1 Trial — a randomized, double-blind, placebo-controlled study to assess the safety and tolerability of GP1681 in healthy adults — is being conducted in partnership with contract research organization, Novotech, and clinical trial unit, CMAX Clinical Research in Australia.

“The world has an urgent need for new COVID-19 treatments, in addition to testing and vaccines. Our clinical trial is designed to evaluate the use of GP1681 as a potential new, cost-effective, shelf-stable, oral drug to treat cytokine storm,” said Whalen.

“We are excited to report that the first cohort has just been successfully completed with positive results, enabling the second cohort to proceed immediately and start dosing this week.

“We are building a powerful treatment platform for respiratory illness that ultimately creates a lasting solution first for COVID-19 cytokine storm and then for a pipeline of indications.”

CytoAgents is a privately held biotechnology company focused on the development of innovative pharmaceutical products for the treatment of cytokine storm related to infectious disease, such as COVID-19 and influenza, as well as non-infectious indications, including CAR T-cell therapy and vaping-induced lung injury.

Innovation Works is a member of the Ben Franklin Technology Partners, one of the nation’s longest-running technology-based economic development programs.

IW and its BFTP counterparts across the state focus on the entrepreneur and innovation as the ultimate engines of growth and deliver crucial resources to help drive that growth, including investing risk capital in emerging technology-based enterprises and established businesses; providing hands-on technical and business expertise to spur enterprise growth and accelerate commercialization activities; and delivering customized solutions that draw on an extensive network of public and private resources, including universities, federal laboratories and research institutions.

For the most up-to-date information on COVID-19, Pennsylvanians should follow www.governor.pa.gov and www.doh.pa.gov. 

Throwback Thursday: New Washington Women Wanted to Vote
Penn State DuBois to offer Nursing Home Administrator Training

Gant Team

Next Post

Throwback Thursday: New Washington Women Wanted to Vote

Please login to join discussion
GantNews.com

© 2020 GantNews

  • About
  • Advertise
  • Newsroom
  • Contact Us

No Result
View All Result
  • Home
  • Top Stories
  • News
    • Top Stories
    • A & E
    • Business News
    • Crime
    • Local News
    • Explore Jefferson
    • Features
    • Health News
      • Health & Wellness
    • Sports
      • Local Sports
  • Obituaries
  • Opinions
  • Classifieds
    • Real Estate
  • Health & Wellness

© 2020 GantNews

Welcome Back!

Login to your account below

Forgotten Password? Sign Up

Create New Account!

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In